Cardionomic

01 / WHAT IT BUILT

What the company did

Cardionomic, Inc. was a privately held medical device company developing a novel therapy for acute decompensated heart failure (ADHF), a condition that hospitalizes over 1 million Americans annually. Backed by venture capital and strategic investors — including the Cleveland Clinic Foundation, Abbott Laboratories and New Enterprise Associates (NEA) — it spent several years developing the Cardiac Pulmonary Nerve Stimulation (CPNS) System: electrical stimulation delivered via a temporary catheter in the pulmonary artery, targeting the root cause of heart failure by stimulating autonomic cardiac nerves to restore autonomic balance. Pilot studies showed significantly less worsening of acute heart failure, increased fluid loss without worsening renal function, and improved quality of life at thirty days. In April 2025 it entered a definitive agreement to sell its assets; in May 2025 Catheter Precision, Inc. (VTAK), through its 82%-owned subsidiary Cardionomix, completed the acquisition of Cardionomic's heart-failure assets.

03 / EVENT HISTORY

Events in the structured record

1. 2025
   Asset sale

   Catheter Precision Form 8-K (filed 8 May 2025): Cardionomic, Inc. (Delaware) had ceased operations and assigned its assets to Cardionomic (assignment for the benefit of creditors), LLC under California ABC law. On 5 May 2025, Catheter Precision subsidiary Cardionomix purchased remaining patents/trademarks of the Cardiac Pulmonary Nerve Stimulation (CNPS) system for 1,000,000 Catheter Precision shares plus a $1.5 million promissory note.